Selective treatment of endothelial somatostatin receptors
First Claim
Patent Images
1. A method for inhibiting angiogenesis in a human patient in need of such inhibition, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR1.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides for the use of somatostatin receptor selective ligands (selective for SSTR1 or SSTR4) to treat human endothelial cells and to formulate medicaments for human use. The medicaments may for example be used to treat an angiogenic disease. In various embodiments, the angiogenic disease may for example be macular degeneration or a solid tumor. The SSTR1 or SSTR4 selective agonists may include the SSTR1 agonist (des-AA1,2,5 [DTrp8,IAamp9]SS).
45 Citations
20 Claims
- 1. A method for inhibiting angiogenesis in a human patient in need of such inhibition, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR1.
- 2. A method for inhibiting angiogenesis in a human patient in need of such inhibition, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR4.
- 3. A method for treating age-related macular degeneration in a human patient in need of such treatment, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR1.
- 4. A method for treating age-related macular degeneration in a human patient in need of such treatment, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR4.
- 5. A method for inhibiting the angiogenic activity of human endothelial cells in a patient in need of such inhibition comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR1.
- 6. A method for inhibiting the angiogenic activity of human endothelial cells in a patient in need of such inhibition comprising administering to said patient an effective amount of a somatostatin receptor ligand that binds with greater affinity to SSTR4 than to any other somatostatin receptor.
- 9. A method for treating cancer by inhibiting solid tumour angiogenesis which comprises administering to a human patient in need of such treatment an effective amount of a somatostatin receptor ligand that binds SSTR1.
- 10. A method for treating cancer by inhibiting solid tumour angiogenesis which comprises administering to a human patient in need of such treatment an effective amount of a somatostatin receptor ligand that binds SSTR4.
Specification